The FDA has given Navidea Biopharmaceuticals fast-track status for a new indication for the company's Lymphoseek radiopharmaceutical. Navidea will submit a supplemental new drug application before the end of the year. Lymphoseek was first approved for lymphatic mapping in breast cancer and melanoma and is being considered for head and neck cancer.

Full Story:
RTT News

Related Summaries